Study Details

Back
Study ID 8273-CL-0202
Study Title An open-label, study of the oral administration of ASP8273 in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor-naïve patients with non-small cell lung cancer harboring EGFR mutations
Clinicaltrials.gov Identifier NCT02500927
Compound Name ASP8273 / naquotinib mesilate
Medical Indication or Disease Non-small cell lung cancer
Study Sponsor Astellas Pharma Inc.
Collaborator Not Applicable
Study Start Date 25-Jun-2015
Study Completion Date 09-Jun-2017
Clinical Study Result
Select the language
English
Plain Language Summary
Select the language
Japanese

QUICK SEARCH

USEFUL LINKS